(Q35064214)

6 August 2017

1 reference

title

Endocrine causes of impotence (nondiabetes). (English)

1 reference

6 August 2017

1 reference

Jeremy P W Heaton

1

1 reference

6 August 2017

Alvaro Morales

series ordinal

2

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Urologic Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

30

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

73-81

1 reference

The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

One hundred impotent men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Endocrine dysfunction in impotence: incidence, significance and cost-effective screening

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Clinical review 24: Androgens in the aging male

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Validation of a screening questionnaire for androgen deficiency in aging males

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Visually stimulated erection in castrated men.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Oral androgens in the treatment of hypogonadal impotent men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Androgen and sleep-related erections

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Ultrasonic testicular texture and size in 444 men from the general population: correlation to semen quality

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Medical therapies for erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Androgen and progestagen effects on plasma lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Transdermal testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Treatment of primary hypogonadism in men by the transdermal administration of testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Disparate serum free testosterone concentrations and degrees of hypothalamo-pituitary-luteinizing hormone suppression are achieved by continuous versus pulsatile intravenous androgen replacement in men: a clinical experimental model of ketoconazole-

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Liquorice consumption and salivary testosterone concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Effects of an environmental anti-androgen on erectile function in an animal penile erection model

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Vascular effects of environmental oestrogens: implications for reproductive and vascular health

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Is routine endocrine testing of impotent men necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Routine prolactin measurement is not necessary in the initial evaluation of male impotence

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Is management of impotence with sildenafil changing clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Erectile dysfunction--the paradigm changes but the challenges remain

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Severe erectile dysfunction is a marker for hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Elevation of prolactin levels by atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Ectopic production of prolactin by colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Evaluation of pituitary microadenomas with dynamic MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Current management of prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Pergolide as primary therapy for macroprolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Quinagolide in the management of prolactinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Clinical features and differential diagnosis of pituitary tumours with emphasis on acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Impotence in medical clinic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Association between plasma lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

Do lipid-lowering drugs cause erectile dysfunction? A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900115-5

7 January 2021

10.1016/S0094-0143(02)00115-5

Identifiers

DOI

1 reference

6 August 2017

1 reference